KSB 304

Drug Profile

KSB 304

Latest Information Update: 28 Jul 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Medicine & Dentistry of New Jersey
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Ulcerative colitis

Most Recent Events

  • 27 Jul 2004 Discontinued - Preclinical for Ulcerative colitis in United Kingdom (parenteral)
  • 25 Sep 2003 KS Biomedix Holdings has been acquired by Xenova Group
  • 28 Aug 2003 DanioLabs and KS Biomedix have entered into an agreement to investigate a colon epithelial protein in the UK for ulcerative colitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top